Identification of FGF21mRNA, protein and the effect of recombinant FGF21 on cardiac function and infarct size.

<p>FGF21 mRNA [<b>Fig. 2A1</b>] and protein expression [<b>Fig. 2A2</b>]; βKlotho mRNA [<b>Fig. 2A3</b>] and protein expression [<b>Fig. 2A4</b>] in isolated rat cardiomyocytes [A] and rat heart [B]. Fig<b>.</b> 1B:Immunocyto/histochemistry and confocal analysis of FGF21 protein in isolated adult rat cardiomyocytes [<b>B1</b>] and rat heart [<b>B2</b>]. MW.- Molecular Weight Marker for PCR products; BP.- Base Pairs; kDa.-kilo daltons. <b>Fig. 2C</b>-(<b>a</b>): Trace recordings of left ventricular developed pressure [LVDP (mmHg)] and left ventricular contractility (dp/dt) in control (saline treated) groups; and <b>Fig. 2C</b>-(<b>b</b>):[LVDP-mmHg] and dp/dt ratio in FGF21 treated groups - following 30 mins of global ischemia and 120 mins reperfusion. <b>Fig. 2D:</b> Rate pressure product [RPP (mmHg/min)] during global ischemia and reperfusion with or without FGF21 treatment [**<i>P</i><0.01 vs. control]. <b>Fig. 2E</b>: Graphical representation of infarct area (%) in rat hearts treated with or without FGF21. Data shown are means ± SEM (n = 6, in triplicates). ***P<0.001; **P<0.01 vs. control.